Stocks and InvestingStocks and Investing
Tue, March 1, 2022
Mon, February 28, 2022
Sun, February 27, 2022
Fri, February 25, 2022

Matthew Kaplan Maintained (UTHR) at Strong Buy with Decreased Target to $203 on, Feb 25th, 2022


Published on 2024-10-27 19:51:37 - WOPRAI, Matthew Kaplan
  Print publication without navigation


Matthew Kaplan of Ladenburg Thalmann, Maintained "United Therapeutics Corporation" (UTHR) at Strong Buy with Decreased Target from $231 to $203 on, Feb 25th, 2022.

Matthew has made no other calls on UTHR in the last 4 months.



There is 1 other peer that has a rating on UTHR. Out of the 1 peers that are also analyzing UTHR, all agrees with Matthew's Rating of Hold. Following is the relevant analyst calls for the last 4 months


  • Julian Harrison of "BTIG" Initiated at Hold on, Friday, February 11th, 2022